Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PPDI - Pharmaceutical Product Development, Inc. -- Ignore unavailable to you. Want to Upgrade?

To: Phaedrus who wrote (31)	6/25/1998 9:58:00 PM
From: Eman03	Read Replies (1) \| Respond to of 71

I partially agree with you. Yes, in the short term, existing clients and engagements probably won't be impacted. However, all future competitive sales opportunities might be. If you were their competitor, wouldn't you ensure that the pharma buyer knew about the letter before he/she made his/her decision? It probably won't kill every opportunity, but you can be sure that it will affect some of them. What about the timing of the insider sales? Here's my theory: The letter was received 6/10. How long do you think it took the FDA to send the letter after the incident took place? Let's for argument say 3 weeks (remember, it's a gov't agency. 8 weeks is probably more likely). That puts the incident before the insider sales. Also, didn't PPDI's rebuttal say that a physician did not mess up the data? If he didn't, who did? A PPDI employee?